published meta-analysis   sensitivity analysis   studies

chloroquine and derivatives in COVID-19 mild to moderate - Summary of results

OutcomeTE95% CInkI2ROBPub. bias deathsdetailed resultsCoalition Covid-19 Brazil I (Cavalcanti)-Hydroxychloroquine, 2020 1.47 [0.48; 4.52] HC-nCoV (Shanghai), 2020 1.00 [0.02; 53.89] 1.43[0.49; 4.21]Coalition Covid-19 Brazil I (Cavalcanti)-Hydroxychloroquine, 2020, HC-nCoV (Shanghai), 202020%362moderatenot evaluable clinical deteriorationdetailed resultsCoalition Covid-19 Brazil I (Cavalcanti)-Hydroxychloroquine, 2020 1.21 [0.69; 2.12] 1.21[0.69; 2.12]Coalition Covid-19 Brazil I (Cavalcanti)-Hydroxychloroquine, 202010%332moderatenot evaluable PCR-negative conversiondetailed resultsHC-nCoV (Shanghai), 2020 0.46 [0.04; 5.75] 0.46[0.04; 5.75]HC-nCoV (Shanghai), 202010%30moderatenot evaluable adverse eventsdetailed resultsCoalition Covid-19 Brazil I (Cavalcanti)-Hydroxychloroquine, 2020 1.74 [1.10; 2.75] HC-nCoV (Shanghai), 2020 1.45 [0.26; 8.01] 1.72[1.10; 2.68]Coalition Covid-19 Brazil I (Cavalcanti)-Hydroxychloroquine, 2020, HC-nCoV (Shanghai), 202020%406moderatenot evaluable0.25.01.0relative treatment effectwww.metaEvidence.org2021-01-25 20:53 +01:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 90 - treatments: 508,656,657 - roots T: 290